Taboo populations, foods, and restrictions of Repotrectinib in Laos
Repotrectinib, as a targeted therapy drug, must be strictly followed in terms of contraindications, dietary restrictions, and usage limitations to ensure medication safety and effectiveness. The following provides a detailed explanation from three aspects: taboo groups, taboo foods, and special restrictions.
1. Taboo population
(1) Pregnant women
Based on animal research showing the risk of fetal malformation, it is contraindicated during pregnancy. Before medication, it is necessary to confirm the pregnancy status of women of childbearing age, and effective contraceptive measures should be taken during the treatment period and 2 months after discontinuation of medication.
(2) Lactating women
The medication may be secreted through breast milk, and it is recommended to suspend breastfeeding during the treatment period and within 10 days after the last administration.
(3) Severe liver dysfunction
Child Pugh Class C patients are contraindicated, and close monitoring of transaminase and bilirubin levels is necessary for mild to moderate liver dysfunction.
2. Forbidden foods
(1) Yuzu and its products
The furan coumarin contained in grapefruit can significantly inhibit CYP3A metabolic enzymes, leading to an abnormal increase in blood drug concentration and an increased risk of toxicity.
(2) Alcoholic beverages
May increase the burden on the liver and synergistically increase central inhibitory effects with medication. It is recommended to completely abstain from alcohol during treatment.
3. Usage restrictions
(1) Driving operation restrictions
During the medication period, driving vehicles or operating heavy machinery is prohibited as it may cause dizziness and cognitive impairment.
(2) Pre - and post-operative management
Medication should be stopped for at least 5 days before elective surgery, and after major surgery, it is necessary to ensure complete wound healing (usually ≥ 2 weeks) before resuming medication.
(3) Drug interactions
It is prohibited to use potent CYP3A inhibitors (such as clarithromycin) or inducers (such as rifampicin) in combination, and the dosage needs to be adjusted or replaced with alternative drugs.
4. Special monitoring requirements
(1) Liver function monitoring
ALT/AST should be tested every 2 weeks during the first month of treatment. If jaundice or transaminase levels exceed 3 times the upper limit, medication should be stopped immediately.
(2) Pulmonary function monitoring
Newly diagnosed respiratory distress or cough require chest CT examination for interstitial lung disease, and medication will be permanently discontinued upon diagnosis.
Disclaimer：《Taboo populations, foods, and restrictions of Repotrectinib in Laos》Edited and sorted by Seagull Pharmacy's editors. Please contact us in time if there is any infringement. In addition, the suggestions for drug usage, dosage and disease mentioned in the article are only for medical staff's reference, and can not be used as any basis for medication！